-
1 Comment
ADMA Biologics, Inc is currently in a long term downtrend where the price is trading 26.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
ADMA Biologics, Inc's total revenue rose by 36.8% to $14M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-19K since the same quarter in the previous year.
Finally, its free cash flow fell by 34.0% to $-36M since the same quarter in the previous year.
Based on the above factors, ADMA Biologics, Inc gets an overall score of 3/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US0008991046 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.48 |
|---|---|
| Target Price | 25.6667 |
| Market Cap | 4B |
| PE Ratio | 18.71 |
| Dividend Yield | None |
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ADMA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026